While pivotal clinical trials and meta-analyses demonstrated the clinical benefits of SGLT2 inhibitors on HF-related adverse outcomes in patients with HFrEF [41, 50, 65], there is a lack of ample evidence to support the clinical benefits of SGLT2 inhibitors in the context of frail or older patients. This evidence concerns the gene SLC5A2 and hydrops fetalis.